These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1448 related items for PubMed ID: 11801463

  • 21. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
    Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B.
    Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
    [Abstract] [Full Text] [Related]

  • 22. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
    Shan D, Ledbetter JA, Press OW.
    Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
    [Abstract] [Full Text] [Related]

  • 23. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ.
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [Abstract] [Full Text] [Related]

  • 24. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 25. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 15; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 26. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop.
    von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, Daniel PT.
    Oncogene; 2003 Apr 17; 22(15):2236-47. PubMed ID: 12700660
    [Abstract] [Full Text] [Related]

  • 27. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 28. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.
    Clin Cancer Res; 2005 Jul 01; 11(13):4857-66. PubMed ID: 16000584
    [Abstract] [Full Text] [Related]

  • 29. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
    Mattila AM, Meri S.
    Scand J Immunol; 2008 Aug 01; 68(2):159-68. PubMed ID: 18702746
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 01; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 34. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
    Alas S, Bonavida B, Emmanouilides C.
    Anticancer Res; 2000 Sep 01; 20(5A):2961-6. PubMed ID: 11062708
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 36. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 37. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S, Ng CP, Bonavida B.
    Clin Cancer Res; 2002 Mar 01; 8(3):836-45. PubMed ID: 11895917
    [Abstract] [Full Text] [Related]

  • 38. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab.
    Daniels I, Abulayha AM, Thomson BJ, Haynes AP.
    Apoptosis; 2006 Jun 01; 11(6):1013-23. PubMed ID: 16544097
    [Abstract] [Full Text] [Related]

  • 39. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M.
    Haematologica; 2006 Feb 01; 91(2):176-83. PubMed ID: 16461301
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.